WFRF:(Dantanarayana A.)
Sökning: WFRF:(Dantanarayana A.) > Neurotoxicity with ...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04824naa a2200697 4500 | |
| 001 | oai:gup.ub.gu.se/311804 | |
| 003 | SwePub | |
| 008 | 240528s2022 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://gup.ub.gu.se/publication/3118042 URI |
| 024 | 7 | a https://doi.org/10.1097/qad.00000000000030912 DOI |
| 040 | a (SwePub)gu | |
| 041 | a eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a McMahon, J. H.4 aut |
| 245 | 1 0 | a Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal |
| 264 | c 2021-09-29 | |
| 264 | 1 | b Ovid Technologies (Wolters Kluwer Health),c 2022 |
| 520 | a Objective: The aim of this study was to examine whether administering both vorinostat and disulfiram to people with HIV (PWH) on antiretroviral therapy (ART) is well tolerated and can enhance HIV latency reversal. Design: Vorinostat and disulfiram can increase HIV transcription in PWH on ART. Together, these agents may lead to significant HIV latency reversal. Methods: Virologically suppressed PWH on ART received disulfiram 2000 mg daily for 28 days and vorinostat 400 mg daily on days 8-10 and 22-24. The primary endpoint was plasma HIV RNA on day 11 relative to baseline using a single copy assay. Assessments included cell-associated unspliced RNA as a marker of latency reversal, HIV DNA in CD4(+) T-cells, plasma HIV RNA, and plasma concentrations of ART, vorinostat, and disulfiram. Results: The first two participants (P1 and P2) experienced grade 3 neurotoxicity leading to trial suspension. After 24 days, P1 presented with confusion, lethargy, and ataxia having stopped disulfiram and ART. Symptoms resolved by day 29. After 11 days, P2 presented with paranoia, emotional lability, lethargy, ataxia, and study drugs were ceased. Symptoms resolved by day 23. CA-US RNA increased by 1.4-fold and 1.3-fold for P1 and P2 respectively. Plasma HIV RNA was detectable from day 8 to 37 (peak 81 copies ml(-1)) for P2 but was not increased in P1 Antiretroviral levels were therapeutic and neuronal injury markers were elevated in P1. Conclusion: The combination of prolonged high-dose disulfiram and vorinostat was not safe in PWH on ART and should not be pursued despite evidence of latency reversal. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
| 653 | a clinical trial | |
| 653 | a disulfiram | |
| 653 | a latency reversal | |
| 653 | a neurotoxicity | |
| 653 | a vorinostat | |
| 653 | a histone deacetylase inhibitor | |
| 653 | a safety | |
| 653 | a Immunology | |
| 653 | a Infectious Diseases | |
| 653 | a Virology | |
| 700 | 1 | a Evans, V. A.4 aut |
| 700 | 1 | a Lau, J. S. Y.4 aut |
| 700 | 1 | a Symons, J.4 aut |
| 700 | 1 | a Zerbato, J. M.4 aut |
| 700 | 1 | a Chang, J.4 aut |
| 700 | 1 | a Solomon, A.4 aut |
| 700 | 1 | a Tennakoon, S.4 aut |
| 700 | 1 | a Dantanarayana, A.4 aut |
| 700 | 1 | a Hagenauer, M.4 aut |
| 700 | 1 | a Lee, S.4 aut |
| 700 | 1 | a Palmer, S.4 aut |
| 700 | 1 | a Fisher, K.4 aut |
| 700 | 1 | a Bumpus, N.4 aut |
| 700 | 1 | a Heck, C. J. S.4 aut |
| 700 | 1 | a Burger, D.4 aut |
| 700 | 1 | a Wu, G. X.4 aut |
| 700 | 1 | a Zuck, P.4 aut |
| 700 | 1 | a Howell, B. J.4 aut |
| 700 | 1 | a Zetterberg, Henrik,d 1973u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xzethe |
| 700 | 1 | a Blennow, Kaj,d 1958u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xbleka |
| 700 | 1 | a Gisslén, Magnus,d 1962u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xgissm |
| 700 | 1 | a Rasmussen, T. A.4 aut |
| 700 | 1 | a Lewin, S. R.4 aut |
| 710 | 2 | a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi4 org |
| 773 | 0 | t Aidsd : Ovid Technologies (Wolters Kluwer Health)g 36:1, s. 75-82q 36:1<75-82x 0269-9370x 1473-5571 |
| 856 | 4 8 | u https://gup.ub.gu.se/publication/311804 |
| 856 | 4 8 | u https://doi.org/10.1097/qad.0000000000003091 |
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- McMahon, J. H.
- Evans, V. A.
- Lau, J. S. Y.
- Symons, J.
- Zerbato, J. M.
- Chang, J.
- visa fler...
- Solomon, A.
- Tennakoon, S.
- Dantanarayana, A ...
- Hagenauer, M.
- Lee, S.
- Palmer, S.
- Fisher, K.
- Bumpus, N.
- Heck, C. J. S.
- Burger, D.
- Wu, G. X.
- Zuck, P.
- Howell, B. J.
- Zetterberg, Henr ...
- Blennow, Kaj, 19 ...
- Gisslén, Magnus, ...
- Rasmussen, T. A.
- Lewin, S. R.
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Infektionsmedici ...
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Neurologi
- Artiklar i publikationen
- Aids
- Av lärosätet
- Göteborgs universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
